Therapeutic DNA Vaccine for Chronic Hepatitis B
The present invention provides a therapeutic DNA vaccine and vaccine treatment method for chronic hepatitis B. A therapeutic DNA vaccine, HB-100, is capable of inducing T helper type1 (Th1) and cellular immune responses that are known to be required for resolution of chronic hepatitis B. HB-100 comprises 1) an efficient expression vector, 2) Hepatitis B Virus nucleotide sequences encoding most HBV antigens to induce polyclonal, multi-epitope specific T cell immune responses, 3) a genetically engineered cytokine Interleukin-12 to induce strong Th1 and cellular immune responses. The efficacy rate of combination therapy with lamivudine and HB-100 can reach more than 50%, whereas the efficacy of lamivudine alone was previously reported to be less than 20%.
Benefits and Applications
The invention can be used for the therapy of chronic hepatitis B
This invention comprises a specific immunotherapeutic strategy that is aimed to cure chronic hepatitis B patients by induced HBV-specific immune responses
Therefore, this strategy can be applied for the development of "immunotherapeutic vaccines" for other serious diseases like AIDS, chronic hepatitis C, TB, etc.
Intellectual Property Status
Patent pending (US)
Nature Biotechnology 2002, 20, 381-386
Interested parties call 1.617.283.2182 or Contact Us
|Visit MVSSolutions.com for info about our technology development services. Visit MVSSolutions.biz for info about our enterprise development & business services. Visit MVSSolutions.us for info about our government contractor services.|
Conducting the Business of Science SM
HOME | WHO WE ARE | WHAT WE DO | AFFILIATIONS | CONTACT
US | PRIVACY STATEMENT | JOBS | NEWS